Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma· 2021 · 1,495 citations
2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial· 2021 · 414 citations
3. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era· 2010 · 1,616 citations
4. The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy· 2019 · 6 citations
5. Real-World Practice Patterns and Outcomes in Veterans with Relapsed/Refractory Diffuse Large B-Cell Lymphoma· 2020 · 13 citations